U.S. Pharma Tariffs Spare India’s Generic Drugmakers — but Leave Investors Jittery

Trump's pharma tariffs will make the world a sicker place

When US President Donald Trump announced a 100% tariff on imported branded pharmaceuticals from October 1, 2025, markets across Asia trembled. Shares of leading drugmakers in India, Japan, and Australia shed billions in value within hours. But while investors felt the sting first, the true cost of Trump’s tariff tantrum will be borne by patients […] The post Trump’s pharma tariffs will make the world a sicker place appeared first on Asia Times.

Pharma tariffs: Trump keeps Indian drug-makers on tenterhooks - The Tribune

The Tribune Editorial: India mainly supplies low-cost generic drugs to the US; fortunately, these are not covered under the new tariff regime.

U.S. pharma tariffs spare India’s generic drugmakers — but leave investors jittery

Investors of Indian pharmaceutical companies are worried about the prospect of further escalation amid U.S. trade tensions.

European Drugmakers to Bear Brunt of New U.S. Tariffs, India Less Exposed: GTRI

Get latest articles and stories on Business at LatestLY. European countries are expected to face the most immediate and severe impact from the new U.S. tariffs on imported branded or patented pharmaceutical products, while India may remain less affected for now, according to a press release by the Global Trade Research Initiative (GTRI). Business News | European Drugmakers to Bear Brunt of New U.S. Tariffs, India Less Exposed: GTRI.

Trump’s pharma tariffs won’t impact India for now, says expert

Trump’s pharma tariffs won’t impact India for now, says expert   Washington: Bhaskar Chakravorti, the Dean of Global Business at The Fletcher School of Law and Diplomacy at Tufts University, said that Trump’s decision to impose 100 per cent tariffs on pharmaceuticals won’t impact India, at least for now. In an exclusive interview with IANS on […] The post Trump’s pharma tariffs won’t impact India for now, says expert   appeared first on Mangalor…

Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvo

US President Trumps 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving Indias generic exports largely unaffected, experts say. The tariff, effective October 1, spooked pharma stocks but poses minimal immediate risk. India exported $9.8 billion in pharma to the US in FY25. Tariffs on furniture and trucks may benefit India, while bilateral trade talks continue.